CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated

B7H3 cancer programmePositive
AI Analysis

Summary

Jefferies maintains a 'buy' rating on GSK, viewing the company's B7H3 cancer programme as undervalued by the market.

Importance:2/10
Sentiment:
0.50
analyst_ratingoncologybuy_rating
Related Companies

Read the original article

Published by yahoo_finance on September 29, 2026 11:30 AM

Read Original